Jeremy Abramson

Dr. Jeremy Abramson is a Professor of Medicine at Harvard Medical School, Director of the Jon and Jo Ann Hagler Center for Lymphoma, and a Clinician Investigator at Massachusetts General Hospital. His work focuses on Lymphoid Malignancies with specialization in B-cell and T-cell lymphomas.

• Harvard Medical School - Professor of Medicine
• Massachusetts General Hospital - Director, Hagler Center for Lymphoma
• Field: Hematology & Oncology

Dr. Abramson's research explores lymphoma immunotherapy, targeted cancer treatments, and clinical trial design. He investigates novel therapeutic targets like CD19, MYC rearrangements, and antineoplastic chemotherapy protocols.

Recent work focuses on CAR T-cell therapies and bispecific antibodies for large B-cell lymphomas. Key publications include phase 3 trials on glofitamab-GemOx and liso-cel in Lancet and Blood journals.

Awarded Fellow of the American College of Physicians, Dr. Abramson actively participates in NCCN guideline development and maintains clinical focus on hematologic malignancies. His email: jabramson@mgh.harvard.edu